Linagliptin plus metformin combination was as effective at lowering hemoglobin A1c as glimepiride plus metformin, and with weight loss and less hypoglycemia SAN DIEGO, June 24, 2011 /PRNewswire/ -- ...

INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--EX US, UK and UAE Medical Media Only. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a 24-week open label arm ...

In Korean adults with type 2 diabetes, combination sitagliptin and metformin as first-line therapy showed a greater improvement in glycemic control and fasting plasma glucose at 30 weeks vs.

Boehringer Ingelheim and Eli Lilly and Company announced phase III study results for linagliptin (proposed trade name Trajenta in Europe), demonstrating improved glycaemic control in adults with type ...

Study data for a combination with metformin show a hint of a minor added benefit because symptomatic hypoglycemia occurs less frequently, experts report after an investigation. Albiglutide (trade name ...

The addition of the highly selective, once-daily dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin (Januvia), compared with glimepiride (Amaryl), to background metformin therapy provides similar ...

New Delhi : Mascot Health Series Pvt.Ltd has received the Drug Controller General of India’s (DCGI) approval for its triple combination diabetes treatment. Mascot claims to be the first CDMO to launch ...

Canagliflozin (trade name: Invokana) has been approved since November 2013 as monotherapy and in various combination therapies for adults with type 2 diabetes mellitus when diet and exercise alone do ...

RIDGEFIELD, Conn. and INDIANAPOLIS, June 16, 2014 /PRNewswire/ -- Two phase III clinical trials studying the efficacy and safety of the investigational compound empagliflozin in type 2 diabetes (T2D) ...

Linagliptin was compared with glimepiride in T2D patients for whom metformin was inappropriate due to intolerance or contraindication. HbA1c levels in patients treated with linagliptin remained stable ...